Selexipag for the treatment of chronic thromboembolic pulmonary hypertension

Abstract

Selexipag significantly improved PVR and other haemodynamic variables in patients with CTEPH, although exercise capacity remained unchanged. Further large-scale investigation is necessary to prove the role of selexipag in CTEPH.